uniQure N.V.
$24.60-0.36%($-0.09)
TickerSpark Score
51/100
27
Valuation
40
Profitability
55
Growth
84
Health
50
Momentum
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a QURE research report →
52-Week Range25% of range
Low $8.73
Current $24.60
High $71.50
Companywww.uniqure.com
uniQure N. V. , a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases.
- CEO
- Matthew Craig Kapusta
- IPO
- 2014
- Employees
- 209
- HQ
- Amsterdam, NL
Price Chart
+60.61% · this period
Valuation
- Market Cap
- $1.54B
- P/E
- -7.39
- P/S
- 85.02
- P/B
- 10.34
- EV/EBITDA
- -9.44
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 74.14%
- Op Margin
- -1057.48%
- Net Margin
- -1154.42%
- ROE
- -145.81%
- ROIC
- -26.48%
Growth & Income
- Revenue
- $16.10M · -40.64%
- Net Income
- $-198,971,000 · 16.94%
- EPS
- $-3.46 · 29.67%
- Op Income
- $-187,827,000
- FCF YoY
- 4.37%
Performance & Tape
- 52W High
- $71.50
- 52W Low
- $8.73
- 50D MA
- $18.90
- 200D MA
- $26.11
- Beta
- 0.87
- Avg Volume
- 3.31M
Get TickerSpark's AI analysis on QURE
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 8, 26 | Abi-Saab Walid | other | 25,000 |
| May 8, 26 | Abi-Saab Walid | sell | 25,000 |
| May 8, 26 | Abi-Saab Walid | sell | 20,000 |
| May 8, 26 | Abi-Saab Walid | other | 25,000 |
| Mar 4, 26 | O'Keefe Kylie | other | 19,800 |
| Mar 4, 26 | O'Keefe Kylie | other | 31,900 |
| Feb 25, 26 | O'Keefe Kylie | other | 0 |
| Feb 25, 26 | O'Keefe Kylie | other | 180,000 |
| Mar 4, 26 | Kapusta Matthew C | other | 70,600 |
| Mar 4, 26 | Kapusta Matthew C | sell | 14,581 |
Our QURE Coverage
We haven't published any research on QURE yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate QURE Report →Similar Companies
VRDN+10.39%
Viridian Therapeutics, Inc.
$17.63
GPCR+2.76%
Structure Therapeutics Inc.
$36.87
EWTX+4.42%
Edgewise Therapeutics, Inc.
$32.82
OCUL+0.50%
Ocular Therapeutix, Inc.
$8.03
GLPG+2.52%
Galapagos N.V.
$27.28
VERA+4.12%
Vera Therapeutics, Inc.
$34.62
NUVB+6.13%
Nuvation Bio Inc.
$4.50
CLDX+2.49%
Celldex Therapeutics, Inc.
$30.90